Key Highlights

  • BioVie shares settled up about 10% to 11%, near $2.38 to $2.40, versus Friday's $2.16.
  • The last on-treatment visit is complete in ADDRESS-LC, a Phase 2 study of bezisterim for neurological Long COVID.
  • About 200 adults were randomized 1:1 versus placebo in the fully grant-funded trial.
  • Topline data on cognition and fatigue is targeted by the end of September 2026.

BioVie Inc. (NASDAQ: BIVI) shares settled up about 10% to 11%, near $2.38 to $2.40, versus Friday's $2.16, after the company said the last on-treatment visit is complete in ADDRESS-LC, a Phase 2 study of bezisterim for neurological Long COVID symptoms including brain fog and fatigue.

What Happened

About 200 adults were randomized 1:1 versus placebo in the trial, which is fully funded by a U.S. Department of War grant, meaning the company is not spending its own cash to complete the treatment phase. Topline data on cognition and fatigue is targeted by the end of September 2026, with a one-month virtual follow-up nearly complete.

Market Reaction

Shares rose as investors responded to the completed treatment phase, a meaningful step for a micro-cap given that no FDA-approved drug currently exists for Long COVID.

Outlook

The topline data readout targeted for the end of September 2026 represents a binary near-term catalyst; a positive result could support a meaningful re-rating from BioVie's current market capitalization, while a mixed result would leave the Long COVID thesis unresolved.